Treatment of cytomegaloviral pneumonia with high-dose acyclovir and human leukocyte interferon.
Thirteen recipients of bone marrow transplants were given high-dose acyclovir and alpha-interferon (Cantell interferon) for the treatment of biopsy-proven cytomegaloviral pneumonia. Three patients survived. Doses of acyclovir between 500 and 1,000 mg/m2 of body surface area (peak plasma levels, 7-86 micrograms/ml) and doses of interferon between 2 X 10(4) and 40 X 10(4) units/kg per day (peak serum levels, 5-608 units/ml) were given. No consistent antiviral effect was seen despite the large doses employed. Possible marrow toxicity associated with this regimen occurred in five patients, neurologic symptoms in two, and nephrotoxicity in one. Thus, treatment with high-dose acyclovir plus alpha-interferon was moderately toxic but ineffective against cytomegaloviral pneumonia after bone marrow transplantation.
D000212:Acyclovir / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000209:etiology; D009422:Nervous System Diseases / Q000209:etiology; D011024:Pneumonia, Viral / Q000188:drug therapy / Q000628:therapy*
D007370:Interferon Type I; D000212:Acyclovir